Efficacy of immune checkpoint inhibitors in different types of melanoma
Ernesto Rossi, Giovanni Schinzari, Brigida Anna Maiorano, Giulia Indellicati, Alessandro Di Stefani, Monica Maria Pagliara, Simona Maria Fragomeni, Erika V. De Luca, Maria Grazia Sammarco, Giorgia Garganese, Jacopo Galli, Maria Antonietta Blasi, Gaetano Paludetti, Giovanni Scambia, Ketty Peris, Giampaolo Tortora
Abstract
Immunotherapy can be used for cutaneous, mucosal, uveal and conjunctival melanoma. Nevertheless, we cannot expect the same benefit from checkpoint inhibitors for all the types of melanoma. The different biological features can explain the variable efficacy. The main results obtained with immune checkpoint inhibitors in the various types of melanoma were reviewed.
Topics & Concepts
MelanomaImmunotherapyImmune checkpointMedicineImmune systemIpilimumabImmunologyCancer researchCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesOcular Oncology and Treatments